Quick Answer
IMMUNIC, INC. reported Diluted EPS of $0.62 per share (loss) for fiscal year 2025.
IMMUNIC, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.62 | +38.0% |
| 2024 | -$1.00 | +52.6% |
| 2023 | -$2.11 | +44.2% |
| 2022 | -$3.78 | +3.8% |
| 2021 | -$3.93 | -39.9% |
| 2020 | -$2.81 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | +45.8% | +35.0% |
| June 30, 2025 | -$0.20 | +4.8% | +20.0% |
| March 31, 2025 | -$0.25 | +16.7% | -4.2% |
| September 30, 2024 | -$0.24 | +52.9% | -14.3% |
| June 30, 2024 | -$0.21 | +61.1% | +30.0% |
| March 31, 2024 | -$0.30 | +48.3% | +41.2% |
| September 30, 2023 | -$0.51 | +26.1% | +5.6% |
| June 30, 2023 | -$0.54 | +25.0% | +6.9% |
- IMMUNIC, INC. showed an increase of +38.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, IMMUNIC, INC.’s diluted eps has grown by 77.9% (from $2.81 per share (loss) to $0.62 per share (loss)).
- The most recent figure is from IMMUNIC, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: